Abstract
AbstractAptamer‐drug conjugate has been developed as a potential class of targeted therapeutics, which using aptamer as tumor recognition elements could targeted deliver the conjugated chemically toxic drug to tumor site. One of the keys to the success of aptamer‐drug conjugate is terminal modification of aptamer to facilitate the conjugation with drugs. Herein, a novel terminal amino‐modified nucleolin aptamer which using solketal as raw material was developed. Moreover, its paclitaxel conjugate wherein the aptamer coupled with paclitaxel derivatives by amidation was also conducted. The easily available raw materials, stable structure, together with its simplicity of operation, gives it the potential for use on an industrial scale.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
